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Abstract
Background: Glutamate-mediated excitotoxicity, primarily through N-methyl-D-aspartate (NMDA) receptors, may
be an important cause of retinal ganglion cells (RGCs) death in glaucoma and several other retinal diseases. Bis(7)-
tacrine is a noncompetitive NMDA receptors antagonist that can prevent glutamate-induced hippocampal neurons
damage. We tested the effects of bis(7)-tacrine against glutamate-induced rat RGCs damage in vitro and in vivo.
Results: In cultured neonatal rats RGCs, the MTT assay showed that glutamate induced a concentration- and time-
dependent toxicity. Bis(7)-tacrine and memantine prevented glutamate-induced cell death in a concentration-
dependent manner with IC50 values of 0.028 μM and 0.834 μM, respectively. The anti-apoptosis effects of bis(7)-
tacrine were confirmed by annexin V-FITC/PI staining. In vivo, TUNEL analysis and retrograde labeling analysis
found that pretreatment with bis(7)-tacrine(0.2 mg/kg) induced a significant neuroprotective effect against
glutamate-induced RGCs damage.
Conclusions: Our results showed that bis(7)-tacrine had neuroprotective effects against glutamate-induced RGCs
damage in vitro and in vivo, possibly through the drug’s anti-NMDA receptor effects. These findings make bis(7)-
tacrine potentially useful for treating a variety of ischemic or traumatic retinopathies inclusive of glaucoma.
Background
Glutamate is a major excitatory neurotransmitter in the
central nervous system, including the retina[1,2]. It is
released by the presynaptic cells and acts on N-methyl-
D-aspartate (NMDA), a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA), and kainite (KA)
receptors [3]. If excessive amounts of glutamate are
released or if glutamate clearance is insufficient, neuro-
nal death will result in a process known as excitotoxi-
city. The glutamate receptor-mediated excitotoxicity has
been associated to various diseases of the brain and eye,
which include Alzheimer’s disease[4], retinal ischemia
[5,6] and glaucoma[7,8]. Although retinal ganglion cells
(RGCs) express all of three receptor subtypes, the gluta-
mate toxicity is primarily mediated by NMDA receptors
[9-11].
Glaucoma, a neurodegenerative disease[12], is asso-
ciated with selective death of retinal ganglion cells [13].
The disease is characterized by an elevation in intraocu-
lar pressure (IOP), which leads to increased glutamate
levels [14]. Vitreal glutamate levels are elevated in dogs
[15] and humans with primary glaucoma [16], and also
in monkeys with experimentally induced chronic glau-
coma[16]. Lowering IOP is the current main treatment
for glaucoma, yet disease progression continues to occur
even in patients with significant IOP reduction[17].
Therefore lowering IOP is inadequate for glaucoma
patients [12,18]. Efforts have been made to attempt to
discover appropriate drugs or chemicals (neuroprotec-
tants) that can be taken orally to slow down retinal
ganglion cell death and have negligible side-effects [19].
Memantine is an uncompetitive NMDA receptor
antagonist which is prescribed for the treatment of Alz-
heimer’s disease [20]. However, two recent parallel clini-
cal trials conducted to test the efficacy of memantine as
a neuroprotectant for glaucoma were unsuccessful[21].
The results of the trials showed that memantine had no
significant effects in preserving visual function.
Until now, there has been no neuroprotective agent indi-
cated for the treatment of glaucoma. A neuroprotectant
that has a single mode of action like memantine has a lim-
ited positive effect in slowing down ganglion cell death
[19]. Pharmacological agents that simultaneously affect
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multiple biological mechanisms are consequently desired.
This has been referred to as the “cocktail” approach [22].
One-drug-multiple-targets approach in the treatment of
neurodegenerative diseases is possible way forward [19,23].
Beside NMDA receptor antagonism, other strategies
have been investigated in the development of neuropro-
tective therapies, which include voltage-dependent cal-
cium channel blockade [24,25], nitric oxide synthase
(NOS) inhibition [26,27], and so on. Bis(7)-tacrine (1,7-
N-heptylene-bis-9,9’-amino-1,2,3,4-tetrahydroacridine), a
dimeric acetylcholinesterase (AChE) inhibitor derived
from anti-Alzheimer’s drug tacrine, possesses remark-
able neuroprotective activities through concurrent inhi-
bition of AChE [28,29], NMDA receptor[30] and nitric
oxide synthase [31,32]. Moreover, bis(7)-tacrine attenu-
ates neuronal apoptosis by regulating L-type voltage-
dependent calcium channels(VDCCs) [33]. Recent
studies showed that bis(7)-tacrine prevented glutamate-
induced excitotoxicity by selectively inhibiting NMDA
receptors in primary cultured cerebellar granule neurons
(CGNs), without the involvement of the other two iono-
tropic glutamate receptors, AMPA receptor and KA
receptor [30,34,35].
Based on these evidence, we hypothesis that bis(7)-
tacrine attenuate glutamate-induced retinal ganglion
cells damage through the blockade of NMDA receptors.
We tested the effect of bis(7)-tacrine in two models of
glutamate excitotoxity, RGCs in culture with glutamate
and intravitreal injection of glutamate. The results
showed that bis(7)-tacrine reduced glutamate-induced
retinal ganglion cells damage in vitro and in vivo.
Results
Identification of cultured RGCs
The purity of isolated RGCs was assessed by fluorescent
microscope (IX71, Olympus, Japan) using a UV filter
that permitted the visualization of fluorogold fluores-
cence (Fig. 1). RGCs were labeled by fluorogold in a ret-
rograde manner. After a two-step immunopanning
procedure, approximately 87.8% (1896/2158 cells) of the
collected cells were labeled by fluorogold. Because it is
difficult to obtain uniform labeling, a small number of
RGCs were probably not identified by retrograde trans-
port, and the purity of the preparations was therefore
underestimated.
Bis(7)-tacrine prevents glutamate-induced cell death
more potently than memantine
Glutamate toxicity was found to be concentration- and
time-dependent, which was consistent with previous
reports[9,36]. At 3 days in vitro, RGCs were exposed
continuously to 25-300 μM glutamate for 24 h and 50
μM glutamate alone at different times. Cell viability
was measured by MTT assay. Glutamate induced a
concentration- dependent loss in neuronal viability
starting from 25 μM and peaking at 300 μM (Fig. 2A).
Glutamate at 50 μM induced a time-dependent neuronal
death starting at 12 h and culminating at 36 h (Fig. 2B).
RGCs were pretreated with 1 μM bis(7)-tacrine for 2 h
and exposed to different concentrations of glutamate for
24 h. With the increase of glutamate concentrations, the
neuroprotective effects of bis(7)-tacrine gradually
decreased and completely lost when RGCs were exposed
Figure 1 Identification of cultured rat RGCs. Phase contrast
image (A) and fluorescence image (B) of RGCs purified from a
5-day-old rat that had received injections of fluorogold into the
superior colliculi 1 day after birth. The cells were cultured for 1 days
under control conditions. Scale bar, 50 μm.
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to over 300 μM glutamate (Fig. 2A). Bis(7)- tacrine at
1 μM retained its neuroprotective effects for at least
60 h after glutamate stimulation (Fig. 2B). RGCs were
pretreated with the gradually increasing concentrations
of bis(7)-tacrine or memantine for 2 h and then exposed
to 50 μM glutamate for 24 h. It was found that bis(7)-
tacrine and memantine prevented glutamate-induced
cell death in a concentration-dependent manner with
IC50 values of 0.028 μM and 0.834 μM, respectively
(Fig. 2C). Bis(7)-tacrine inhibited the glutamate-induced
cell death more potently than memantine.
Bis(7)-tacrine reduces glutamate-induced apoptosis of
RGCs in vitro
The anti-apoptotic effects of bis(7)-tacrine were studied
using an Annexin-V FITC/PI assay. The results demon-
strated that 50 μM glutamate induced apoptosis in a
time-dependent manner and bis(7)-tacrine could prevent
glutamate-induced apoptosis (Fig. 3). Although the
initial 6 h of glutamate exposure did not change the
percentage of apoptotic cells relative to the control
group, there were marked increases in the percentage of
apoptotic cells after 12 h (18.48 ± 2.76%; p < 0.05) and
24 h (45.12 ± 6.15%; p < 0.05). Bis(7)-tacrine inhibited
glutamate-induced damage to RGCs in a concentration-
dependent manner. At 12 h, bis(7)-tacrine at 0.01 μM
has a tendency to reduce glutamate-induced damage
(P > 0.05), but bis(7)-tacrine (0.1 μM, 1 μM), as well as
memantine (1 μM,10 μM), decreased the percentage of
apoptotic cells to 9.78 ± 0.97%, 7.92 ± 1.14%, 13.92 ±
2.98%, 8.28 ± 1.87% respectively (all p < 0.05). At 24 h,
all the concentrations of two drugs, bis(7)-tacrine (0.01
μM, 0.1 μM, 1 μM) and memantine (1 μM,10 μM),
reduced effectively the percentage of apoptotic cells, but
only with bis(7)-tacrine (1 μM) show no significant
increase in the percentage of apoptotic cells in compari-
son with control group.
Bis(7)-tacrine reduces glutamate-induced apoptosis of
RGCs in vivo
Apoptotic changes in the retina were assessed by the
TUNEL method. Little TUNEL positivity was observed
in the control (PBS-injected) group (Fig. 4A). However,
at 18 h after glutamate was injected into the eyes, pro-
minent TUNEL-positive cells were found in the ganglion
cell layer(GCL) and the inner nuclear layer (INL)
(Fig. 4B). The density of TUNEL-positive cells in GCL
was 64.87 ± 8.83 cells/mm in the glutamate group
whereas it was 54.50 ± 8.15/mm in the animals receiv-
ing bis(7)-tacrine at 0.1 mg/kg (P <0.05) and 42.87 ±
7.82/0.5 mm when the dose of bis(7)-tacrine was 0.2
mg/kg (P < 0.01). Compared with the glutamate group,
there was no statistically significant reduction when ani-
mals receiving bis(7)-tacrine at 0.05 mg/kg (P > 0.05).
Figure 2 Glutamate (Glu) induces a concentration- and
time-dependent changes and bis(7)-tacrine is more potent
than memantine in preventing the excitotoxicity of glutamate
in the MTT assay. A, at 3 days in vitro, cultured RGCs were
exposed to 1 μM bis(7)-tacrine for 2 h before the addition of
glutamate at the different concentrations indicated. Cell viability
was measured at 24 h by MTT assay. B, compared with normal
neurons, RGCs were preincubated with or without 1 μM bis(7)-
tacrine for 2 h and then exposed to 50 μM glutamate at different
times indicated. Cell viability was measured at the indicated times.
C, graph plotting percentage of neuron survival as a function of
concentrations of bis(7)-tacrine(●)and memantine(○). RGCs were pre-
treated with bis(7)-tacrine (0.001-1 μM) or memantine (0.01-10 μM)
for 2 h before the addition of 50 μM glutamate. At 24 h after the
challenges, cell viability was measured. All of the data, expressed as
percentages of the corresponding control, were means ± SEM of
three separate experiments. *P < 0.05, **P < 0.01 versus glutamate
group in A and C or versus control at the same time in B.
++ P < 0.01 versus glutamate group at the same time in B.
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The results showed that bis(7)-tacrine rescued these
neurons from apoptosis which was induced by gluta-
mate in a dose-dependent manner. Memantine (10 mg/
kg, 20 mg/kg) showed the same protective effects as bis
(7)-tacrine(0.2 mg/kg) (Fig. 4E).
Bis(7)-tacrine protect RGCs in experiments using
retrograde labeling of RGCs
The GCL is composed of about equal numbers of RGCs
and displaced amacrines[37]. To ensure accurate identi-
fication of RGCs, we retrogradely labeled the RGCs in
rats with fluorogold allowing us to selectively label
greater than 99% of the RGCs. In PBS-injected eyes
without glutamate, the mean density of RGCs was
2196.6 ± 155.0 cells/mm2 (n = 6) (Fig. 5A). Fifteen min-
utes after intraperitoneally injection of bis(7)-tacrine
(0.05, 0.1, 0.2 mg/kg), memantine(5, 10, 20 mg/kg) or
PBS, 20 nmol glutamate was injected intravitreally into
the same animals. At 7 days after glutamate injection,
the mean densities of the RGCs in control (PBS-
injected) and experimental (0.05, 0.1, 0.2 mg/kg bis(7)-
tacrine and 5, 10, 20 mg/kg memantine) eyes were 676.5 ±
49.6, 729.3 ± 50.5, 853.0 ± 102.0, 1284.6 ± 99.0, 697.3 ±
42.4, 770.0 ± 85.2, 1148.2 ± 105.0 cells/mm2(n = 6)
(Fig. 5E), respectively, and the different was statistically
significant (PBS vs 0.1 mg/kg bis(7)-tacrine, P = 0.038;
PBS vs 0.2 mg/kg bis(7)-tacrine, P < 0.01; PBS vs 20 mg/
kg memantine, P < 0.01). These data showed that both of
bis(7)-tacrine and memantine possessed neuroprotective
effects against glutamate-induced RGCs death, and bis
(7)-tacrine (0.2 mg/kg) had the same effects as memantine
(20 mg/kg).
Discussion
Glutamate excitotoxicity is thought to contribute to a
broad variety of neurological diseases, including Alzhei-
mer’s disease and glaucoma. In retina tissues, the predo-
minant form of glutamate neurotoxicity is mediated by
overstimulation of the NMDA subtype of glutamate
receptors, which in turn causes an increase of Ca2+
influx, followed by cell death [5,9,38]. Recent research
demonstrated that bis(7)-tacrine prevented glutamate-
induced cerebellar granule neurons (CGNs) apoptosis
through directly blocking NMDA receptors [30,34]. We
show here that bis(7)-tacrine provided in vitro and in
vivo neuroprotective effects on glutamate-induced RGCs
damage. Although the cytoprotective actions of bis(7)-
tacrine have previously been observed in brain neurons
under excitotoxic/ischemic conditions[23,30,34,39], to
our knowledge, this is the first report to elucidate the
neuroprotective action of bis(7)-tacrine on RGCs in
response to glutamate excitotoxicity.
Some researches have reported that RGCs are highly
susceptible to glutamate toxicity in vitro and in vivo
[9,38,40]. First of all, we explored the in vitro effective-
ness of bis(7)-tacrine against glutamate-induced RGCs
damage. In a previous report, glutamate toxicity was
concentration-dependent with a calculated EC50 of 30.8
Figure 3 Bis(7)-tacrine reduces glutamate(Glu)-induced apoptosis of RGCs in vitro. RGCs were cultured with and without glutamate for
6-24 h in the presence or absence of bis(7)-tacrine (0.01-1 μM) or memantine (1-10 μM). Percentage of apopotic cells was detected by
Annexin-V FITC/PI staining by flow cytometry. Apoptotic cells included Annexin V(+)/PI(-) and Annexin V(+)/PI(+) cells. Results were expressed as
the means ± SEM of 7 independent experiments. (*P < 0.05 as compared to the control group for each time point; # P < 0.05 as compared to
the glutamate group for each time point).
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μM[9]. In our study, the MTT assays have shown that
cultured RGCs are highly sensitive to 24 h 50 μM gluta-
mate treatment, which produces 50% or greater cell
death. Furthermore, bis(7)-tacrine, like the NMDA
receptor antagonist memantine, has been confirmed to
attenuate the cytotoxic effect of glutamate. As meman-
tine showed affinity and potency comparable to those of
bis(7)-tacrine in blocking the NMDA receptor [39], we
chose memantine as the positive control in this study.
The minimal effective concentration of bis(7)-tacrine
against glutamate excitotoxicity was approximately 0.01
μM. The combination of data from the MTT assays and
the Annexin V-FITC/PI assays, provided strong evidence
that bis(7)-tacrine was significantly more potent than
memantine in inhibiting glutamate-induced cell damage.
This finding was similar to previous reports in cultured
rat cortical neurons[34].
Next, we verified the neuroprotective effects of bis(7)-
tacrine in animal models of glutamate-induced retinal
injury. The pharmacokinetic research in the body of the
rat showed that bis(7)-tacrine was rapidly and widely
distributed to its target tissues such as brain[41,42]. In a
model of acute focal cerebral ischemic insults in MCAO
rats, bis(7)-tacrine at doses of 0.1 mg/kg and 0.2 mg/kg
significantly reduced ischemic impairment in vivo[23].
In the current study, two animal assays showed that bis
(7)-tacrine(0.2 mg/kg) protected RGCs from glutamate
excitotoxicity, while bis(7)-tacrine(0.05 mg/kg) had no
significant neuroprotective effects.
We cannot definitively state that bis(7)-tacrine was
neuroprotective for retinal ganglion cells alone. In retina
tissues, several cells express NMDA receptors, such as
RGCs and displaced amacrine cells[43] in the retinal
ganglion cell layer (GCL)and bipolar cells[44] in the
inner nuclear layer (INL). These cells are susceptible to
excitotoxic cell death, we did not differentiate between
retinal ganglion cells and other cells.
Neuroprotection was initially studied as a treatment
strategy for various neurological disorders including
stroke, dementia, multiple sclerosis, Alzheimer’s disease
and glaucoma. Despite successful preclinical cell culture
and animal model experiments, most of these therapies
were not successful at the clinical stage of testing
because of either unacceptable side effect profiles or a
lack of efficacy [12,45,46]. High affinity NMDA receptor
antagonists such as MK-801 are undesirable as they
entail nonselective inhibition of tonic glutamate activity
as well as phasic physiological NMDA receptor function
Figure 4 Bis(7)-tacrine reduces glutamate(Glu)-induced apoptosis of RGCs in vivo. Eyes were enucleated at 18 h after intravitreal injection
of glutamate(Glu) (20 nmol) or vehicle. TUNEL staining was performed and TUNEL-positive cells were counted in GCL. (A) A representative
photograph of retina in the vehicle group. (B) A representative photograph of retina in the glutamate group. (C & D) A representative
photograph of retina in the glutamate group with peritoneal injection of bis(7)-tacrine(0.2 mg/kg)(C) or memantine(20 mg/kg)(D). (E) The
number of TUNEL-positive cells in GCL was counted. Each column represents means ± SEM (n = 6). *P < 0.05, **P < 0.01 versus glutamate
group alone. GCL: ganglion cell layer, IPL: inner plexiform layer, INL: inner nuclear layer, ONL: outer nuclear layer. Scale bar, 50 μm.
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[47]. Memantine is a moderate affinity, uncompetitive
NMDA receptor antagonist prescribed for the treatment
of moderate to severe Alzheimer’s disease [48,49]. How-
ever, recent clinical findings showed that there was no
clear benefit after glaucoma patients received meman-
tine; thereby it was suggested that neuroprotectants with
multiple modes of actions were likely to reveal clearer
results than was found for memantine [19].
The preclinical studies demonstrated that bis(7)-
tacrine had low toxicity in animal models[50], and bis
(7)-tacrine possessed multiple physiological activities
including anti-NMDA receptors, anti-AChE, anti-L-
type-voltage-dependent calcium channels(VDCCs), anti-
nitric oxide synthase (NOS) signaling and the regulation
of the downstream signal of NMDA receptors
[28,30,32,33,51]. In the present study, bis(7)-tacrine pre-
vented glutamate-induced RGCs damage possibly by
inhibiting NMDA receptors. At this point, electrophy-
siology studies will be needed to verify the blocking
kinetics of bis(7)-tacrine on three glutamate receptors in
the purified RGCs. What’s more, further calcium ima-
ging studies will be required to determine the role of
calcium permeation through NMDA receptors and
to determine if intracellular calcium is involved in
triggering neuroprotection or inhibiting glutamate
excitotoxicity. Besides inhibiting NMDA receptors, the
other effects of bis(7)-tacrine on RGCs deserves further
study.
Conclusions
In conclusion, our experiments have demonstrated that
bis(7)-tacrine can provide neuroprotection against gluta-
mate-induced retinal ganglion cells damage in vitro and
in vivo. The effects may be achieved through inhibitions
of NMDA receptors. This neuroprotective effects of bis
(7)-tacrine may lead to a novel approach for the treat-
ment of retinopathies, such as glaucoma.
Methods
Animals and reagents
Sprague-Dawley(SD) rats, including 1-3 days rats and
adult male rats, were obtained from the Animal Center
in Tongji Medical College, Huazhong University of
Science and Technology, and were housed in the animal
facility under standard conditions of room temperature
and a 12:12 h light-dark cycle with free access to food
and water. All animal experiments followed the guide-
lines for the care and use of animals established by
Tongji Medical College, Huazhong University of Science
and Technology and adhered to the tenets of the
Figure 5 Effect of bis(7)-tacrine on RGCs following intravitreal injection of glutamate(Glu) (20 nmol). (A) A representative photograph of
RGCs labeled with fluorogold injected into the superior colliculus in normal retina. (B) A representative photograph of fluorogold -labeled RGCs
7 days after intravitreal injection of glutamate. (C & D) A representative photograph of fluorogold -labeled RGCs 7 days after intravitreal injection
of glutamate with daily peritoneal injection of bis(7)-tacrine(0.2 mg/kg)(C) or memantine(20 mg/kg)(D). (E) The number of RGCs was counted.
Each column represents means ± SEM (n = 6). *P < 0.05, **P < 0.01 versus glutamate group alone. Scale bar, 50 μm.
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Declaration of Helsinki. Bis(7)-tacrine was purchased
from Cayman Chemical Co.(USA). Fluorogold was pur-
chased from Biotium (Hayward, USA). Unless noted, all
other reagents were obtained from Sigma (St. Louis,
MO, USA).
Cell culture and purification of RGCs
RGCs from retinas of 1-3 days rats were purified by a
two-step immunopanning procedure. Briefly, the retinal
tissue was dissociated into single cells in EMEM (Gibco,
China) containing 15 U/ml papain and 70 U/ml collage-
nase. The dissociated cells were incubated in a polypro-
pylene tube coated with an anti-rat macrophage
monoclonal IgG (Chemicon International, Inc, CA,
USA) to exclude macrophages, and then incubated in a
tube coated with an anti-rat Thy 1.1 monoclonal IgG
(Chemicon International, Inc, CA, USA). The tube was
gently washed with PBS for five times, and adherent
RGCs were collected by centrifugation at 600 g for
5 minutes.
Before the examinations of effects of bis(7)-tacrine on
RGCs, a preliminary study was conducted to determine
purity of RGCs after the two-step immunopanning pro-
cedure. After 1-day-old rats were anesthetized by intra-
peritoneal injection with 10% (w/v) chloral hydrate (350
mg/kg), RGCs were labeled in a retrograde manner by
injecting 4% fluorogold into the superior colliculi. Four
days later, after this immunopanning method, approxi-
mately 87.8% (1896/2158 cells) of the collected cells
were labeled by fluorogold. Next, in further examina-
tions of effects of bis(7)-tacrine on RGCs, RGCs were
used from rats without fluorogold injection and grown
in serum-free medium (Gibco-China), containing 1 mM
glutamine, 10 μg/mL gentamicin, B27 supplement
(1:50), 40 ng/mL each of BDNF and CNTF, and 5 μM
forskolin. RGCs were cultured in a CO2 incubator
(Thermo Lab 2300, USA) with 5% CO2 at 37°C. Before
seeding, the plates were coated with poly-D-lysine (PDL,
70 kDa, 10 μg/ml) at room temperature followed by
overnight incubation with mouse laminin. RGCs were
cultured for 3 days and then exposed them to glutamate
and/or bis(7)-tacrine for MTT assay or annexin-V
FITC/PI assay.
Measurement of neurotoxicity
The percentage of surviving RGCs in the presence of bis
(7)-tacrine and/or glutamate was estimated by determin-
ing the activity of mitochondrial dehydrogenases with 3
(4,5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bro-
mide (MTT) assay [30]. Cells were seeded at a density
of 5000 cells/well in 96-well plates. The assay was per-
formed according to the specifications of the manufac-
turer (MTT kit I; Roche China, Ltd.). Briefly, the rat
RGCs were cultured in 96-well plates, 10 μl of 5 mg/ml
MTT labeling reagent was added to each well contain-
ing cells in 100 μl of medium, and the plate was incu-
bated for 4 h in a humidified incubator at 37°C. After
the incubation, 100 μl of the solvating solution (0.01 N
HCl in 10% SDS solution) was added to each well for
17-18 h. The absorbance of the samples was measured
at a wavelength of 570 nm with 630 nm as a reference
wavelength. Unless otherwise indicated, the extent of
MTT conversion in cells exposed to glutamate is
expressed as a percentage of the control.
Annexin-V FITC/PI assay
Apoptosis was detected using an Annexin-V FITC/PI
detection kit (Jiancheng Biotechnology Co., Ltd., Nanj-
ing, China) according to the manufacturer’s directions.
The cells were digested with 0.125% trypsin, washed
with ice-cold phosphate-buffered saline and resuspended
in binding buffer (5 × 105 cells/ml). Then, the cells were
centrifuged at 1,000 rpm for 5 min at 4°C. After the
supernatant had been discarded, 500 μl of binding buf-
fer, 5 μl of annexin-V-FITC and 5 μl of propidium
iodide (PI) were added to 200 μl of the cell suspension.
After mixing gently, the suspensions were incubated for
15 min at room temperature without light. Finally, the
cells were analyzed by flow cytometry (BD LSRII; BD
Biosciences).
Intravitreal administration of glutamate
Male rats (220-280 g) were anesthetized by intraperito-
neal injection of 10% (w/v) chloral hydrate (350 mg/kg)
and rectal body temperature was maintained at 37°C
with a heating pad during the experiments. The pupils
were dilated with tropicamide and a single dose of 5 μl
of 4 mM glutamate (total amount 20 nmol) in 0.01 M
PBS (pH 7.4) was injected into the vitreous cavity using
32-gauge Hamilton needle and syringe. PBS was admi-
nistered as a control.
TUNEL staining
TUNEL staining was performed according to the manu-
facturer’s protocols (In Situ Cell Death Detection Kit;
Roche China, Ltd.) to detect retinal cell apoptosis
induced by glutamate. Twenty-four rats were divided
into eight groups: three bis(7)-tacrine-treated groups
(0.05, 0.1, 0.2 mg/kg), three memantine-treated groups
(5, 10, 20 mg/kg), a control group, and a glutamate
group. Six eyes per experimental condition were used.
In this study, 18 h after the glutamate injection, rats
were killed with an overdose of chloral hydrate. The
eyes were immediately enucleated and fixed in 4% paraf-
ormaldehyde in PBS for the TUNEL studies. The speci-
mens were then dehydrated and embedded in paraffin
and 5 μm sections were cut. These sections were stained
by the TUNEL method according to the manufacturer’s
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directions. The yellow condensed TUNEL positive cells
were counted under a 20× objective microscope. No
attempt was made to distinguish the cell types in the
GCL, and displaced amacrine cells were not excluded
from the counts. To minimize the variance in cell num-
ber, we counted TUNEL positive cells in the retinal
ganglion cell layer (GCL) manually at 1.0-2.0 mm (both
sides) from the center of the optic disc. The average
number of TUNEL positive cells/eye was obtained from
three sections of each retina.
Retrograde labelling and counting of RGCs
To examine the change in the number of RGCs after
glutamate injection, RGCs were retrogradely labeled
with fluorogold. Twenty-four rats were treated respec-
tively with the same division and administration above
mentioned. Fifteen minutes before intravitreally injection
of glutamate, drugs were intraperitoneally administered
to the rats in a volume of 1.5 mL/kg body weight. Four
days after the glutamate injection, retrograde labeling of
RGCs was made. Briefly, rats were anesthetized by intra-
peritoneally injection with 10% (w/v) chloral hydrate
(350 mg/kg) and then the heads were fixed in a stereo-
taxic apparatus. Fluorogold was microinjected bilaterally
into the superior colliculi(SC) and dorsal lateral genicu-
late nuclei (dLGN) of rats. Three days after the Fluoro-
gold injection (seven days after the glutamate injection),
the animals were killed by an intraperitoneal overdose
injection of chloral hydrate and the eyes were enu-
cleated. Eyes were fixed with 4% paraformaldehyde for 1
h. Retinas were removed from the sclera, divided into
four radial cuts and mounted on slides. Analysis for the
number of fluorogold-labeled RGCs was carried out.
Briefly, Tracer-labeled RGCs counting was performed in
12 areas of 0.072 mm2 each (three areas per retinal
quadrant) at 2/6, 3/6, and 5/6 of the retinal radius
under a fluorescent microscope (Olympus IX71). Data
from 12 areas from each eye were averaged.
Statistical analysis
Data are expressed as mean ± SEM. Statistical signifi-
cance was determined using the ANOVA method fol-
lowed by Dunnett’s test in the case of multiple
comparisons. Single comparisons were performed by Stu-
dent’s t test. Statistical analysis of concentration-response
data was performed using the nonlinear curve-fitting pro-
gram ALLFIT, which uses an ANOVA procedure[34,51].
Values reported for concentration-response analysis are
those obtained by fitting the data to the equation:
Y E EC X= +max / [ ( / ) ]1 50
n
where X and Y are concentration and response,
respectively, Emax is the maximal response, EC50 is the
concentration yielding 50% of maximal effect (EC50 for
activation, IC50 for inhibition), and n is the slope
factor.
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